FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine and deals with histidine-trehalose composition, stable after storage, containing antibody T1h, histidine buffer, trehalose and non-ionic surface-active substance.
EFFECT: invention provides reduction of quantity of highly molecular weight proteins (HMWP) by approximately 20% by weight with respect to initial quantity of HMWP in histidine-trehalose composition within five weeks.
4 cl, 5 ex, 27 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE BINDING PREPARATIONS BASED ON IgG4 | 2013 |
|
RU2644214C2 |
| STABLE LIQUID PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2773747C2 |
| ANTIBODY COMPOSITION | 2015 |
|
RU2743681C2 |
| STABLE AQUEOUS COMPOSITIONS BASED ON ANTIBODIES | 2014 |
|
RU2763787C2 |
| LIQUID COMPOSITION CONTAINING ANTIBODY TO HUMAN INTERLEUKIN-4 RECEPTOR ALPHA | 2020 |
|
RU2814172C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| NEW STABLE COMPOSITIONS FOR FXIA ANTIBODIES | 2018 |
|
RU2775692C2 |
| NEW METHOD FOR STABILIZATION OF A BIOPHARMACEUTICAL MEDICINAL PRODUCT IN MANUFACTURE THEREOF | 2017 |
|
RU2744630C2 |
| HIGHLY CONCENTRATED COMPOSITIONS OF ANTIBODIES TO C5 | 2018 |
|
RU2787595C2 |
| COMPOSITIONS BASED ON BISPECIFIC ANTIBODIES TO IL-4/IL-13 | 2014 |
|
RU2690850C2 |
